Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 15, 2019 - Issue
Submit an article Journal homepage
130
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data

Alexandra Simbrich1 Institute of Epidemiology and Social Medicine, University of Münster, 48149Münster, Germany
,
Jasmine Thibaut1 Institute of Epidemiology and Social Medicine, University of Münster, 48149Münster, Germany
,
Laura Khil1 Institute of Epidemiology and Social Medicine, University of Münster, 48149Münster, Germany;2 Cancer Registry North Rhine-Westphalia, 44801, Bochum, Germany
,
Klaus Berger1 Institute of Epidemiology and Social Medicine, University of Münster, 48149Münster, Germany
,
Oliver Riedel3 Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology – BIPS, 28359Bremen, GermanyCorrespondence[email protected]
&
Niklas Schmedt3 Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology – BIPS, 28359Bremen, Germany;4 InGef – Institute for Applied Health Research Berlin GmbH, 10117Berlin, Germany
Pages 1439-1457 | Published online: 28 May 2019

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Claudia Volpi, Ciriana Orabona, Antonio Macchiarulo, Roberta Bianchi, Paolo Puccetti & Ursula Grohmann. (2019) Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Discovery 14:11, pages 1199-1212.
Read now

Articles from other publishers (6)

KO Jalusic, D Ellenberger, A. Stahmann & K Berger. (2023) Adverse events in MS patients fulfilling or not inclusion criteria of the respective clinical trial – The problem of generalizability. Multiple Sclerosis and Related Disorders 69, pages 104422.
Crossref
Tjalf Ziemssen, Anna Kurzeja, Bogdan Muresan, Jennifer S Haas, Jessica Alexander & Maurice T Driessen. (2022) Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany. Neurodegenerative Disease Management 12:2, pages 93-107.
Crossref
Huah Shin Ng, Feng Zhu, Elaine Kingwell, Yinshan Zhao, Shenzhen Yao, Okechukwu Ekuma, Lawrence W Svenson, Charity Evans, John D Fisk, Ruth Ann Marrie & Helen Tremlett. (2021) Disease-modifying drugs for multiple sclerosis and subsequent health service use. Multiple Sclerosis Journal 28:4, pages 583-596.
Crossref
Sarah Noelle Moeller & Alexandra Simbrich. (2022) Self-perceived versus physician documented adverse events in patients with multiple sclerosis REGIMS-a pharmacovigilance registry for patients with multiple sclerosis in Germany. Multiple Sclerosis and Related Disorders 59, pages 103684.
Crossref
Mozhde Askari, Omid Mirmosayyeb, Elham Moases Ghaffary, Hamed Ghoshouni, Vahid Shaygannejad & Mahsa Ghajarzadeh. (2022) Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders 59, pages 103680.
Crossref
Huah Shin Ng, Jonas Graf, Feng Zhu, Elaine Kingwell, Orhan Aktas, Philipp Albrecht, Hans-Peter Hartung, Sven G. Meuth, Charity Evans, John D. Fisk, Ruth Ann Marrie, Yinshan Zhao & Helen Tremlett. (2022) Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. Frontiers in Immunology 12.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.